ACTUALIDAD

A Phase 3, Two-part (Open-label Followed by Randomized Double-masked Active Controlled) Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection with Ranibizumab in Subjects with wet Age-related Macular Degeneration (wAMD)

 

INVESTIGADOR:

Dr. Álvaro Fernández-Vega Sanz
  RECLUTANDO  

 

A Phase 3, Two-part (Open-label Followed by Randomized Double-masked Active Controlled) Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection with Ranibizumab in Subjects with wet Age-related Macular Degeneration (wAMD)


PATOLOGÍA: Degeneración Macular Asociada a la Edad
TRATAMIENTO: HLX04-O
PROMOTOR: Shanghai Henlius Biotech. Inc.
Codigo del estudio: HLX04- O- wAMD.
Déjanos tus datos
Nos pondremos en contacto contigo
Por favor, activa JavaScript en tu navegador para completar este formulario.
Casillas de verificación